Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. SenzaGen AB's Revenue for the
three
months ended in Mar. 2026 was €1.39 Mil. SenzaGen AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was €1.12 Mil.
Hence, SenzaGen AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.24.
SenzaGen AB (FRA:26S) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
SenzaGen AB Receivables Turnover Related Terms
SenzaGen AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for SenzaGen AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:26S vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, SenzaGen AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SenzaGen AB Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SenzaGen AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where SenzaGen AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SenzaGen AB (FRA:26S) has a Receivables Turnover of 1.24 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on SenzaGen AB and its competitors. According to the industry distribution chart, SenzaGen AB ranks #108 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 53.5%.
Is SenzaGen AB's Receivables Turnover too high?
SenzaGen AB's current Receivables Turnover is 1.24. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. SenzaGen AB's value of 1.24 is 77% below this industry median. Based on the distribution chart, SenzaGen AB ranks #108 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SenzaGen AB has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does SenzaGen AB's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SenzaGen AB ranks #108 out of 202 companies for Receivables Turnover. This places SenzaGen AB in the lower half of its industry. The industry median Receivables Turnover is 5.38. SenzaGen AB's value of 1.24 is 77% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SenzaGen AB's current Receivables Turnover of 1.24 is 77% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on SenzaGen AB and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SenzaGen AB's current Receivables Turnover is 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SenzaGen AB stock overvalued right now?
SenzaGen AB (FRA:26S) has a current Receivables Turnover of 1.24. The stock's GF Value™ is €0.57, compared to a current price of €0.47 — trading 17.2% below its estimated fair value. The current Receivables Turnover is 1.24 and 77% below the Medical Diagnostics & Research industry median of 5.38. SenzaGen AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For SenzaGen AB (FRA:26S), the current Receivables Turnover is 1.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SenzaGen AB (FRA:26S) Overvalued in 2026?
Based on GuruFocus' analysis, SenzaGen AB stock appears to be undervalued.
The current stock price of €0.47 is trading 17.2% below its estimated GF Value™ of €0.57.
Key valuation signals for FRA:26S:
Receivables Turnover: 1.24
GF Value™: €0.57 vs. price of €0.47 (17.2% below fair value)
Industry Position: 77% below the Medical Diagnostics & Research median (#108 of 202)
No single metric tells the full story. See the FRA:26S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SenzaGen AB markets, sells, and performs in vitro testing using its Genomic Allergen Rapid Detection (GARD) platform through its laboratory and a network of contract research organizations. The company provides animal-free testing solutions for chemical compounds used in industries such as cosmetics, chemicals, pharmaceuticals, medical devices, and food and nutrition. Geographically, it operates in the Americas, EMEA, and APAC, with the majority of revenue from EMEA.
72GF Score
Get the complete analysis for FRA:26S
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:26S has been successfully added to your 
